



GlyTech, Inc.

Pioneering breakthrough in the chemical synthesis of Interferon β -1a

Bubendorf/Basel, Switzerland and Kyoto, Japan
July 10, 2013 - GlyTech, Inc. (Kyoto, Japan) and Bachem AG (Bubendorf, Switzerland) informed that they have successfully co-developed a chemical synthesis of Interferon β -1a for industrial scale.

Interferon β -1a is a 166 amino acid long glycosylated protein and an approved drug substance to treat multiple sclerosis with a world market of more than \$ 4 billion. There are currently three recombinant products on the market which are a mixture of at least 10 glycoforms.

Bachem and GlyTech achieved a pioneering breakthrough with the successful chemical synthesis of this protein featuring a specific, single glycosylation. First bioactivity studies demonstrated that the new product is as good as or better than the recombinant Interferon β -1a.

Bachem and GlyTech with their know how in peptide and carbohydrate chemistry are looking forward to a future partnership with a pharma or biotech company interested in conducting all further development activities through to market approval.

About Bachem

Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.

About GlyTech

GlyTech is an independent, technology-based, private company founded in 2012 in Kyoto, Japan. GlyTech is the only company to manufacture human type glycans in kilogram scale and to develop unique glycopeptides and glycoproteins as innovative biochemicals.

Contact:

For further questions, please visit our websites or contact the person below.

Bachem Holding AG **Stephan Schindler, CFO**

Tel.: +41 61 935 2333

Fax: +41 61 935 2324

ir@bachem.com

www.bachem.com

GlyTech, Inc.

Katsura Torii, CBDO

Tel.: +81 75 315 9218

Fax: +81 75 315 9225

glytech-info@glytech.jp

www.glytech.jp